Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2020 1
2021 19
2022 47
2023 55
2024 73
2025 113
2026 58

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean exas treatment (12 results)?
VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP, Hinojosa-Azaola A, Sánchez-Hernández BE, Crispín JC, Apodaca-Chávez E, Ferrada MA, Martín-Nares E. Loeza-Uribe MP, et al. Reumatol Clin (Engl Ed). 2024 Jan;20(1):47-56. doi: 10.1016/j.reumae.2023.12.004. Epub 2023 Dec 29. Reumatol Clin (Engl Ed). 2024. PMID: 38160120 Free article. Review.
Patients with VEXAS syndrome exhibit inflammatory and hematological manifestations that can lead to clinical diagnoses such as relapsing polychondritis, polyarteritis nodosa, Sweet syndrome, and myelodysplastic syndrome. ...The aim of this review is to provide an ov …
Patients with VEXAS syndrome exhibit inflammatory and hematological manifestations that can lead to clinical diagnoses such as …
Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.
Kilic B, Sacin E, Tanin MK, Kilinc OC, Ugurlu S. Kilic B, et al. Ann Hematol. 2025 May;104(5):2617-2630. doi: 10.1007/s00277-025-06382-2. Epub 2025 Apr 27. Ann Hematol. 2025. PMID: 40287866 Free PMC article.
MEDLINE and EMBASE were screened from inception until March 2025. We included patients with VEXAS syndrome who received treatment with azacitidine, JAK inhibitors, IL-6 inhibitors, anti-IL-1, or anti-TNF agents. ...A total of 16 studies and 367 patients with …
MEDLINE and EMBASE were screened from inception until March 2025. We included patients with VEXAS syndrome who received tre …
Treatment Options for VEXAS Syndrome: Rapid Review.
Authors; Goring S, Horton J. Authors, et al. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov. PMID: 38620405 Free Books & Documents. Review. No abstract available.
VEXAS: A review of current understandings and emerging treatment strategies.
Holden R, Jeelal Y, McLean-Tooke A, Pathmanathan K, Nolan D. Holden R, et al. Front Immunol. 2025 Jul 28;16:1644404. doi: 10.3389/fimmu.2025.1644404. eCollection 2025. Front Immunol. 2025. PMID: 40791602 Free PMC article. Review.
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a late-onset autoinflammatory disorder, typically affecting males, caused by somatic mutations in the X-linked gene UBA1 encoding the E1 ubiquitin-activating enzyme. ...Alongside these autoinflamm …
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a late-onset autoinflammatory disorder, typically affect …
VEXAS syndrome: Current clinical, diagnostic and treatment approaches.
Kobak S. Kobak S. Intractable Rare Dis Res. 2023 Aug;12(3):170-179. doi: 10.5582/irdr.2023.01020. Intractable Rare Dis Res. 2023. PMID: 37662628 Free PMC article. Review.
Due to the recent discovery of VEXAS syndrome, ongoing research is being conducted to better understand its pathogenesis, clinical features, and potential treatment options. In this review article, the clinical, diagnostic and treatment approaches of …
Due to the recent discovery of VEXAS syndrome, ongoing research is being conducted to better understand its pathogenesis, clin …
VEXAS syndrome.
Grayson PC, Patel BA, Young NS. Grayson PC, et al. Blood. 2021 Jul 1;137(26):3591-3594. doi: 10.1182/blood.2021011455. Blood. 2021. PMID: 33971000 Free PMC article. Review.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease of adulthood caused by somatic mutations in UBA1 in hematopoietic progenitor cells. ...VEXAS syndrome represents a prototype for a new class of diseases... …
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease of adulthood caused by somati …
VEXAS syndrome.
Nakajima H, Kunimoto H. Nakajima H, et al. Int J Hematol. 2025 Sep;122(3):341-350. doi: 10.1007/s12185-024-03799-9. Epub 2024 May 31. Int J Hematol. 2025. PMID: 38819628 Free PMC article. Review.
VEXAS syndrome is a recently identified, adult-onset autoinflammatory disease caused by somatic mutations in UBA1. ...Treatment of VEXAS syndrome is challenging and no consistently effective therapies have been established. ...
VEXAS syndrome is a recently identified, adult-onset autoinflammatory disease caused by somatic mutations in UBA1. ...Treat …
VEXAS Syndrome-Review.
Zhang Y, Dong X, Wang H. Zhang Y, et al. Glob Med Genet. 2023 Jul 10;10(3):133-143. doi: 10.1055/s-0043-1770958. eCollection 2023 Sep. Glob Med Genet. 2023. PMID: 37501758 Free PMC article. Review.
To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality rate, VEXAS syndrome needs to be taken seriously by physicians in all specialties. This …
To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been …
JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.
Bahramian S, Fazeli P, Rafati A, Demokri S, Memari H, Soheili A, Esmaeili F, Pourmehdi Ardebili M, Erfani H, Vahabi SM. Bahramian S, et al. Dermatol Res Pract. 2025 Sep 12;2025:9127126. doi: 10.1155/drp/9127126. eCollection 2025. Dermatol Res Pract. 2025. PMID: 40977752 Free PMC article. Review.
We aim to investigate the safety and efficacy of JAK-I in the treatment of VEXAS syndrome. Methods: A systematic search was conducted using MeSH terms/keywords related to JAK-I and VEXAS syndrome through PubMed/Medline, Scopus, Web of Science, a …
We aim to investigate the safety and efficacy of JAK-I in the treatment of VEXAS syndrome. Methods: A systematic search …
An update on VEXAS syndrome.
Al-Hakim A, Savic S. Al-Hakim A, et al. Expert Rev Clin Immunol. 2023 Feb;19(2):203-215. doi: 10.1080/1744666X.2023.2157262. Epub 2022 Dec 26. Expert Rev Clin Immunol. 2023. PMID: 36537591 Free article. Review.
Current treatment and management options are discussed. EXPERT OPINION: New rare variants in UBA1 and VEXAS-like UBA1 negative cases are reported. ...Prospective studies are needed to define the optimal supportive and treatment options for patients with varyi …
Current treatment and management options are discussed. EXPERT OPINION: New rare variants in UBA1 and VEXAS-like UBA1 negative …
320 results